6533b82dfe1ef96bd1291576
RESEARCH PRODUCT
Modulation by fenoldopam (SKF 82526) and bromocriptine of the electrically evoked release of vasopressin from the rat neurohypophysis. Effects of dopamine depletion.
J. MeureschK. RackéB. TrappErich Muschollsubject
AgonistVasopressinmedicine.medical_specialtyFenoldopammedicine.drug_classVasopressinsDopamineStimulationFenoldopamIn Vitro TechniquesReceptors DopaminePituitary Gland PosteriorDopamineInternal medicinemedicineAnimalsBromocriptinePharmacologyChemistryRats Inbred StrainsGeneral MedicineBenzazepinesBromocriptineElectric StimulationRatsEndocrinologyVasopressin secretionFemaleSulpiridemedicine.drugdescription
1. Single neurointermediate lobes were fixed by their stalks to a platinum wire electrode and incubated in Krebs-bicarbonate solution. Vasopressin release into the medium was determined by a radioimmunoassay. Vasopressin secretion was increased by electrical stimulation (15 Hz, 10 s trains with 10 s intervals for 10 min). 2. Fenoldopam (SKF 82526) had a dual effect on vasopressin release, 30 nM decreasing (by 30%) and 3 μM increasing (by 32%) the evoked vasopressin secretion. The facilitatory effect of fenoldopam was antagonized in a concentration-dependent manner by flupenthixol but not by sulpiride. Sulpiride (1 μM) prevented the inhibitory effect of fenoldopam (30 μM). 3. After pretreatment of the rats with the dopamine depleting agent, Ro4-1284 (2 mg/kg i.p. 1 h before the experiments), the evoked vasopressin release was decreased by 21% and the inhibitory effect of fenoldopam disappeared, but the facilitatory effect of fenoldopam was already seen at 30 nM. Similarly, bromocriptine (1–10 μM) decreased the evoked vasopressin release from untreated neurointermediate lobes by 30–40% but increased the vasopressin release by 30% after pretreatment with Ro4-1284. 4. The present findings further support the concept that vasopressin from the neurohypophysis is modulated by dopaminergic mechanisms. Facilitatory effects are mediated via D 1 and inhibition via D 2 receptors. The presence of endogenous dopamine seems to be necessary for the inhibitory effects to occur.
year | journal | country | edition | language |
---|---|---|---|---|
1986-04-01 | Naunyn-Schmiedeberg's archives of pharmacology |